Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ce |
RCV003430625 | SCV004157528 | benign | not provided | 2024-06-01 | criteria provided, single submitter | clinical testing | ANK1: BS1, BS2 |
Mayo Clinic Laboratories, |
RCV003430625 | SCV004228205 | uncertain significance | not provided | 2023-05-19 | criteria provided, single submitter | clinical testing | BS1, BS2, BP4, BP7 |
OMIM | RCV000000541 | SCV000020690 | pathogenic | Spherocytosis, type 1, autosomal recessive | 2000-12-01 | no assertion criteria provided | literature only | |
Reproductive Health Research and Development, |
RCV000000541 | SCV001142390 | benign | Spherocytosis, type 1, autosomal recessive | 2020-01-06 | no assertion criteria provided | curation | NG_012820.1(NM_001142446.2):c.127-39554G>A in the ANK1 gene has an allele frequency of 0.02 in African subpopulation in the gnomAD database. 6 homozygous occurrences are observed in the gnomAD database. This variant was reported as -153G-A in a hereditary spherocytosis patient (PMID: 11102985). Benign computational verdict because benign prediction from DANN. Taken together, we interprete this variant as Benign/Likely benign variant. ACMG/AMP criteria applied: BS1, BS2, BP4. |